SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 27.57% in the sales to Rs. 52852.90 millions was observed for the quarter ended September 2022. The sales figure stood at Rs. 41431.50 millions during the year-ago period.Net Profit recorded in the quarter ended September 2022 rise to 49.93% to Rs. 12130.10  millions  compared to R. 8090.70 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 17048.80 millions from 11485.40 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 52852.90 41431.50 27.57 102181.70 78084.40 30.86 155859.80 141160.50 10.41
Other Income 417.10 2842.70 -85.33 2179.20 4959.60 -56.06 11968.80 1920.70 523.15
PBIDT 17048.80 11485.40 48.44 32035.30 16035.70 99.77 38654.40 24490.80 57.83
Interest 927.70 1039.80 -10.78 1798.40 2114.40 -14.95 3881.00 2675.20 45.07
PBDT 16121.10 10445.60 54.33 30236.90 12265.60 146.52 16568.10 20920.00 -20.80
Depreciation 3839.50 3336.40 15.08 7584.50 6405.70 18.40 13499.50 12364.30 9.18
PBT 12281.60 7109.20 72.76 22652.40 5859.90 286.57 3068.60 8555.70 -64.13
TAX 151.50 -981.50 -115.44 404.30 -848.00 -147.68 4068.50 131.70 2989.22
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 12130.10 8090.70 49.93 22248.10 6707.90 231.67 -999.90 8424.00 -111.87
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 32.26 27.72 16.36 31.35 20.54 52.66 24.80 17.35 42.95

Sun Pharma Inds. Share Price

1675.90 0.70 (0.04%)
20-Apr-2026 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.05
Dr. Reddys Lab 1237.50
Cipla 1239.40
Zydus Lifesciences 942.20
Lupin 2327.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×